Biopsy of the prostate guided by transrectal ultrasonography: early experience in a teaching community hospital.
Transrectal ultrasonography (TRUS) was used to guide 277 biopsies of the prostate in 182 patients. The Bard Biopty system was used. Of these 182 patients, 107 (59%) had benign changes, and 75 (41%) had malignant lesions. Of those with cancer, 40% (30/75) had negative results of digital rectal examination (DRE). The cancer detection rate by TRUS was 40.7%, and by DRE alone it was 24.2%. Use of TRUS before transurethral resection of the prostate (TURP) in 47 patients with negative findings on DRE yielded 22 cancerous lesions (47%). We advocate this method in patients with abnormalities detected on DRE or with elevated levels of prostate-specific antigen or prostatic acid phosphatase, and as preoperative screening in patients having TURP because of the potential impact of a preoperative diagnosis of cancer upon the choice of treatment.
Allen
M D
MD
Baptist Medical Center Princeton, Birmingham, Ala 35211.
Embry
B
B
D000368:Aged; D000369:Aged, 80 and over; D000407:Alabama; D000951:Antigens, Neoplasm / Q000302:isolation & purification; D001707:Biopsy, Needle / Q000379:methods*; D006764:Hospitals, Community; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D017430:Prostate-Specific Antigen; D011469:Prostatic Diseases / Q000000981:diagnostic imaging* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D014463:Ultrasonography
D000951:Antigens, Neoplasm; D017430:Prostate-Specific Antigen